The chemical name you provided, **2-(2-methylphenoxy)-N-[2-(4-methylphenyl)-5-benzotriazolyl]acetamide**, refers to a specific organic compound. It is likely a derivative of benzotriazole, a heterocyclic compound with a wide range of applications.
While I cannot provide precise information about the compound's specific research significance without further context, I can shed light on its potential importance:
**Benzotriazoles and their derivatives are known for their:**
* **UV-absorbing properties:** They act as excellent UV stabilizers, protecting materials from photodegradation. This makes them valuable in sunscreen formulations, polymers, and other applications.
* **Antioxidant properties:** Benzotriazoles can scavenge free radicals, preventing oxidative damage. This is relevant for research related to aging, diseases, and material degradation.
* **Bioactivity:** Some benzotriazole derivatives exhibit biological activity, potentially leading to applications in pharmaceuticals, agrochemicals, and other areas.
**The specific structure of 2-(2-methylphenoxy)-N-[2-(4-methylphenyl)-5-benzotriazolyl]acetamide suggests it could be a:**
* **New UV absorber:** The methyl groups on the phenyl rings might influence its UV absorption properties.
* **Novel antioxidant:** The specific functional groups could affect its antioxidant activity.
* **Lead compound for drug discovery:** The structure could be modified to create more potent or specific bioactive agents.
**To understand its true research significance, you would need to consider:**
* **The context of its synthesis:** Why was it synthesized in the first place? What research question was being addressed?
* **Its properties:** How does it compare to other known benzotriazole derivatives? What are its specific UV absorption, antioxidant, or biological activity properties?
* **Its applications:** Has it shown promise in any particular field?
**If you provide more context, I may be able to give you a more specific and relevant answer.**
| ID Source | ID |
|---|---|
| PubMed CID | 1109840 |
| CHEMBL ID | 1612418 |
| CHEBI ID | 94024 |
| Synonym |
|---|
| NCGC00098984-01 |
| OPREA1_485646 |
| OPREA1_029458 |
| EU-0008066 |
| CBKINASE1_001188 |
| 2-(2-methylphenoxy)-n-[2-(4-methylphenyl)-2h-benzotriazol-5-yl]acetamide |
| STK183969 |
| CBKINASE1_013588 |
| AKOS000519062 |
| BRD-K40300908-001-01-2 |
| HMS1797O12 |
| 2-(2-methylphenoxy)-n-[2-(4-methylphenyl)benzotriazol-5-yl]acetamide |
| o8b , |
| bdbm50395186 |
| chembl1612418 , |
| 2-(2-methylphenoxy)-n-[2-(p-tolyl)benzotriazol-5-yl]acetamide |
| sr-01000461653 |
| SR-01000461653-1 |
| CHEBI:94024 |
| 2-(2-methylphenoxy)-n-[2-(4-methylphenyl)-2h-1,2,3-benzotriazol-5-yl]acetamide |
| Q27165777 |
| 2-(2-methylphenoxy)-n-[2-(4-methylphenyl)-5-benzotriazolyl]acetamide |
| Class | Description |
|---|---|
| triazoles | An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 79.4328 | 0.1000 | 20.8793 | 79.4328 | AID588456 |
| ClpP | Bacillus subtilis | Potency | 8.9125 | 1.9953 | 22.6730 | 39.8107 | AID651965 |
| TDP1 protein | Homo sapiens (human) | Potency | 22.1427 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 0.8913 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 0.0669 | 0.3162 | 12.4435 | 31.6228 | AID902; AID904 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 100.0000 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 100.0000 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| HTH-type transcriptional regulator EthR | Mycolicibacterium smegmatis MC2 155 | IC50 (µMol) | 2.9000 | 2.9000 | 2.9000 | 2.9000 | AID699054 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| AID699051 | Binding affinity to Mycobacterium smegmatis mc2 155 EthR assessed as protein thermal unfolding at 20 uM by SYPRO Orange dye based thermal shift assay | 2012 | Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14 | Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. |
| AID699052 | Inhibition of EthR in Mycobacterium tuberculosis H37Rv-GFP infected in mouse Raw 264.7 cells assessed as boosting of 0.1 uM ethionamide-induced microbial growth inhibition at 10 uM by automated fluorescent confocal microscopy | 2012 | Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14 | Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. |
| AID699054 | Inhibition at EthR in Mycobacterium smegmatis mc2 155 assessed as reactivation of beta-glucuronidase activity measured over 48 hrs by Spectrophotometry | 2012 | Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14 | Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. |
| AID699053 | Inhibition of EthR in Mycobacterium tuberculosis H37Rv-GFP infected in mouse Raw 264.7 cells assessed as compound concentration allowing 0.1 uM ethionamide to inhibit 50% microbial growth by automated fluorescent confocal microscopy | 2012 | Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14 | Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||